BioSpace News Archive

Cannabis Bioscience International Holdings (OTC Pink: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatment methodologies for breast and pancreatic cancers, for legal review and subsequent registration.

According to latest report, the global cancer biologics market size was USD 103.98 billion in 2023, calculated at USD 111.40 billion in 2024, and is expected to reach around USD 207.24 billion by 2033, expanding at a CAGR of 7.14% from 2024 to 2033.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”) is pleased to announce that today it has filed its audited annual financial statements and accompanying management’s discussion and analysis

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company’s Board of Directors. Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company’s Board.

Ubix Therapeutics, Inc., a biotechnology company discovering and developing innovative oncology therapeutics based on targeted protein degradation (TPD), announced today that it has entered into an exclusive license agreement with Yuhan to develop and commercialize preclinical androgen receptor (AR) degrader program, UBX-103.

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, confirmed that it will file its Biologics License Application for approval of Ryoncil® in the treatment of children with steroid-refractory acute graft versus host disease with the U.S. Food and Drug Administration next week.

Kedrion Biopharma Inc. announced that it has established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy Yimmugo® in the U.S., following its Biologic License Application approval by the U.S. Food and Drug Administration on June 13, 2024.

IASO biotechnology presented the clinical data and single-cell analysis of the fully human anti-BCMA CAR T cell therapy for the treatment of central nervous system autoimmunity in an oral presentation at the 2024 European Academy of Neurology Annual Meeting.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows: